About APRINOIA
APRINOIA is a company based in Taipei (Taiwan) founded in 2015.. APRINOIA has raised $51.1 million across 3 funding rounds from investors including The Michael J. Fox Foundation, KTB Network and Yantai Dongcheng Biochemicals. The company has 15 employees as of December 31, 2022. APRINOIA operates in a competitive market with competitors including Biogen, Denali Therapeutics, Annexon, Entrada Therapeutics and Adamas Pharma, among others.
- Headquarter Taipei, Taiwan
- Employees 15 as on 31 Dec, 2022
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Aprinoia Therapeutics Llc
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$51.1 M (USD)
in 3 rounds
-
Latest Funding Round
$40 M (USD), Series C
Dec 28, 2021
-
Investors
The Michael J. Fox Foundation
& 8 more
-
Employee Count
15
as on Dec 31, 2022
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Unlock access to complete
Unlock access to complete
Funding Insights of APRINOIA
APRINOIA has successfully raised a total of $51.1M across 3 strategic funding rounds. The most recent funding activity was a Series C round of $40 million completed in December 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 3
- Last Round Series C — $40.0M
-
First Round
First Round
(16 Jan 2018)
- Investors Count 9
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec, 2021 | Amount | Series C - APRINOIA | Valuation | Yantai Dongcheng Biochemicals | |
| May, 2019 | Amount | Grant - APRINOIA | Valuation |
investors |
|
| Jan, 2018 | Amount | Series B - APRINOIA | Valuation | Daiwa Corporate Investment , KTB Network |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in APRINOIA
APRINOIA has secured backing from 9 investors, including institutional and venture fund investors. Prominent investors backing the company include The Michael J. Fox Foundation, KTB Network and Yantai Dongcheng Biochemicals. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private fund focused on debt and equity investments in medium and large-sized businesses
|
Founded Year | Domain | Location | |
|
Private equity firm investing in multiple sectors
|
Founded Year | Domain | Location | |
|
Venture capital fund
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by APRINOIA
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - APRINOIA
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Aprinoia Comparisons
Competitors of APRINOIA
APRINOIA operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Biogen, Denali Therapeutics, Annexon, Entrada Therapeutics and Adamas Pharma, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Therapies for neurodegenerative and immunology disorders are developed.
|
|
| domain | founded_year | HQ Location |
Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's.
|
|
| domain | founded_year | HQ Location |
Developer of antibodies to treat complement-mediated neurodegenerative diseases
|
|
| domain | founded_year | HQ Location |
Biologics platform developed for intracellular delivery in rare diseases.
|
|
| domain | founded_year | HQ Location |
Pharmacokinetic profiles of approved drugs are enhanced for CNS therapeutics.
|
|
| domain | founded_year | HQ Location |
T-cell-based therapies for autoimmune and degenerative diseases are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Aprinoia
Frequently Asked Questions about APRINOIA
When was APRINOIA founded?
APRINOIA was founded in 2015 and raised its 1st funding round 3 years after it was founded.
Where is APRINOIA located?
APRINOIA is headquartered in Taipei, Taiwan.
Is APRINOIA a funded company?
APRINOIA is a funded company, having raised a total of $51.1M across 3 funding rounds to date. The company's 1st funding round was a Series B of $11.1M, raised on Jan 16, 2018.
How many employees does APRINOIA have?
As of Dec 31, 2022, the latest employee count at APRINOIA is 15.
What does APRINOIA do?
APRINOIA was founded in 2015 and is based in Taipei, Taiwan, within the biotechnology sector. Diagnostics and therapeutics for neurodegenerative disorders are developed, with emphasis placed on tau, alpha-synuclein, and related proteins linked to diseases such as Alzheimers and Parkinsons. The lead candidate, APNmAb005, is a humanized anti-tau antibody designed to target tau aggregates in tau-related conditions, including Alzheimers disease.
Who are the top competitors of APRINOIA?
APRINOIA's top competitors include Alector, Intra-Cellular Therapies and Entrada Therapeutics.
Who are APRINOIA's investors?
APRINOIA has 9 investors. Key investors include The Michael J. Fox Foundation, KTB Network, Yantai Dongcheng Biochemicals, IMM Holdings, and Taian Biotechnology.